Medication Risk Management During Intensive Physical Rehabilitation

Abstract

Intensive physical rehabilitation is a cornerstone in the recovery of patients with complex medical conditions, but it is also a period marked by significant changes in pharmacotherapy needs and heightened risk of medication-related problems. This review synthesizes current evidence on medication risk management during intensive rehabilitation, focusing on epidemiology, pathophysiology, risk factors, clinical features, diagnosis, treatment strategies, emerging advances, and guideline-based recommendations. The aim is to equip healthcare professionals with a comprehensive understanding of the challenges and best practices for optimizing medication safety and efficacy during rehabilitation.

Introduction

Medication risk management is a critical component of care for patients undergoing intensive physical rehabilitation, given the dynamic physiological changes, polypharmacy, and comorbidities common in this population. The rehabilitation phase often involves medication adjustments for pain, spasticity, infections, cardiovascular conditions, and psychiatric comorbidities, which can interact with the physical demands of therapy and alter pharmacokinetics. Recent evidence underscores the importance of proactive strategies to prevent adverse drug events (ADEs), optimize therapeutic outcomes, and support functional recovery. This article reviews the scientific and clinical aspects of medication risk management in this unique setting.

Epidemiology / Disease Burden

Medication-related problems are prevalent among patients in intensive rehabilitation settings, with studies reporting ADE rates ranging from 10% to 30% depending on patient complexity and medication regimens. Older adults, who constitute a substantial proportion of rehabilitation patients, are particularly vulnerable due to polypharmacy, chronic illnesses, and age-related physiological changes. The consequences of medication-related harm in this context include prolonged hospitalization, functional decline, increased healthcare costs, and higher readmission rates. Epidemiological data highlight the need for systematic risk assessment and mitigation strategies during rehabilitation.

Pathophysiology

The pathophysiological basis for increased medication risk during rehabilitation is multifactorial. Intensive physical activity can influence the absorption, distribution, metabolism, and excretion of drugs. For example, enhanced muscle perfusion and increased metabolic demands may alter the pharmacokinetics of lipophilic drugs and those with a narrow therapeutic index. Additionally, conditions such as renal impairment, hepatic dysfunction, and altered gastrointestinal motility—common in patients recovering from acute illness—can further modify drug effects and toxicity profiles. Understanding these mechanisms is vital for clinicians to anticipate and manage medication risks proactively.

Risk Factors

Key risk factors for medication-related problems during rehabilitation include advanced age, polypharmacy (use of five or more medications), cognitive impairment, fluctuating renal or hepatic function, high-intensity exercise regimens, and the presence of multiple comorbidities. Other notable factors are poor nutritional status, drug-drug and drug-disease interactions, and transitions of care (e.g., from acute hospital to rehabilitation facility). Identifying these risk factors enables targeted interventions and closer monitoring during rehabilitation.

Clinical Features

Adverse drug events during intensive rehabilitation may present as falls, delirium, hypotension, bleeding, electrolyte disturbances, and inadequate symptom control, among others. The clinical manifestations are often subtle and may be misattributed to the underlying disease or the rehabilitation process itself. For example, sedating medications may exacerbate fatigue and impede participation in therapy, while antihypertensives may precipitate orthostatic hypotension during exercise. A high index of suspicion and regular clinical assessment are essential for early detection.

Diagnosis

Diagnosis of medication-related problems relies on thorough medication reconciliation, comprehensive review of clinical status, and close monitoring for new or worsening symptoms. Tools such as the Beers Criteria and STOPP/START criteria can help identify potentially inappropriate medications in older adults. Laboratory monitoring, including renal and hepatic function tests, drug levels (where appropriate), and electrolyte panels, is crucial for timely diagnosis and intervention. Communication among multidisciplinary team members, including pharmacists, physicians, and rehabilitation therapists, enhances diagnostic accuracy.

Treatment & Management

Effective medication risk management in rehabilitation involves individualized medication review, dose adjustment based on current physiology, and the judicious use of non-pharmacological interventions. Deprescribing unnecessary medications, optimizing dosing schedules to align with therapy sessions, and employing safer drug alternatives are cornerstone strategies. Education of patients and caregivers regarding the risks and signs of ADEs, as well as clear documentation and communication across care transitions, further reduce medication-related harm. Collaboration with clinical pharmacists is strongly recommended for comprehensive medication management.

Recent Advances / Emerging Therapies

Recent advances in medication safety during rehabilitation include the integration of clinical decision support systems (CDSS) into electronic health records, enabling real-time alerts for drug interactions and dosing errors. Pharmacogenomic testing is gaining traction as a tool for personalizing therapy, particularly for patients on complex regimens or those with unpredictable responses. Additionally, mobile health applications and remote monitoring technologies can support ongoing assessment and timely intervention. Emerging evidence supports the use of multidisciplinary medication review rounds and structured protocols for high-risk drug classes, such as anticoagulants and CNS-active agents.

Guideline Recommendations

Current guidelines from organizations such as the American Geriatrics Society and the Society of Hospital Medicine emphasize systematic medication reconciliation at every transition of care, regular risk assessment, and active deprescribing where appropriate. Guideline-based recommendations also include the utilization of validated screening tools for ADEs, prioritization of non-pharmacological strategies for symptom management, and involvement of pharmacists in rehabilitation teams. Documentation of medication changes and rationale, along with patient-centered education, are essential components of guideline-concordant care.

Conclusion

Medication risk management during intensive physical rehabilitation is a complex, multidisciplinary process requiring a proactive, individualized approach. Recognition of epidemiological trends, underlying pathophysiology, and patient-specific risk factors is critical for preventing medication-related harm. Advances in technology, interprofessional collaboration, and adherence to evidence-based guidelines offer promising avenues for improving outcomes. Ultimately, optimizing medication safety during rehabilitation not only supports functional recovery but also contributes to the overall quality of patient care.